Intellia Therapeutics (NTLA) Expected to Announce Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is anticipated to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect Intellia Therapeutics to post earnings of ($1.26) per share and revenue of $11.39 million for the quarter.

Intellia Therapeutics Price Performance

Shares of NASDAQ NTLA opened at $8.87 on Thursday. The company has a 50 day simple moving average of $8.44 and a 200 day simple moving average of $11.66. The firm has a market cap of $918.20 million, a PE ratio of -1.63 and a beta of 2.23. Intellia Therapeutics has a 1 year low of $5.90 and a 1 year high of $28.18.

Wall Street Analysts Forecast Growth

NTLA has been the subject of a number of recent analyst reports. Wells Fargo & Company decreased their target price on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research report on Monday, March 3rd. BMO Capital Markets decreased their target price on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research report on Friday, January 10th. Chardan Capital decreased their target price on shares of Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating for the company in a research report on Friday, February 28th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and set a $13.00 target price (down previously from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $36.68.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.